Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Pacira BioSciences, Inc. - Common Stock
(NQ:
PCRX
)
24.65
+0.18 (+0.74%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 17, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Pacira BioSciences, Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
Pacira BioSciences Reaffirms Commitment to Enhancing Value for All Shareholders
April 17, 2025
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 11, 2025
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences Announces Settlement of U.S. Patent Litigation for EXPAREL
April 07, 2025
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences Announces First Patient Dosed in Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee
April 03, 2025
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
April 01, 2025
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences Confirms Receipt of Director Nominations from DOMA Perpetual
March 14, 2025
From
Pacira BioSciences
Via
GlobeNewswire
PCRX DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Pacira BioSciences, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 14 Deadline in Securities Class Action – PCRX
March 13, 2025
From
The Rosen Law Firm PA
Via
GlobeNewswire
PACIRA BIOSCIENCES 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against Pacira BioSciences, Inc. - PCRX
March 11, 2025
From
Kahn Swick & Foti, LLC
Via
Business Wire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira
March 11, 2025
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira
March 09, 2025
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
Faruqi & Faruqi Reminds Pacira BioSciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 14, 2025 - PCRX
March 07, 2025
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 06, 2025
From
Pacira BioSciences
Via
GlobeNewswire
PACIRA BIOSCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRX
March 05, 2025
From
SkyMedia, LLC
Via
GlobeNewswire
PACIRA BIOSCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRX
March 04, 2025
From
Kahn Swick & Foti, LLC
Via
GlobeNewswire
PCRX DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel Before Important March 14 Deadline in Securities Class Action – PCRX
March 03, 2025
From
The Rosen Law Firm PA
Via
GlobeNewswire
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira
March 03, 2025
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
Lowey Dannenberg Notifies Pacira Biosciences, Inc. (“Pacira” or the “Company”) (NASDAQ: PCRX) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
February 28, 2025
From
Lowey Dannenberg, P.C.
Via
GlobeNewswire
PCRX STOCKHOLDERS: Contact Robbins LLP for Information About the Pacira BioSciences, Inc. Class Action Before the Expiration of the Lead Plaintiff Deadline
February 27, 2025
From
Robbins LLP
Via
GlobeNewswire
Pacira BioSciences Reports Fourth Quarter and Full-Year 2024 Financial Results
February 27, 2025
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences Acquires Remaining Equity Stake of GQ Bio
February 27, 2025
From
Pacira BioSciences
Via
GlobeNewswire
Pacira BioSciences to Participate in Fireside Chat at Two Healthcare Conferences in March
February 26, 2025
From
Pacira BioSciences
Via
GlobeNewswire
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PCRX
February 24, 2025
From
The Rosen Law Firm PA
Via
GlobeNewswire
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PCRX
February 21, 2025
From
The Rosen Law Firm PA
Via
GlobeNewswire
Lowey Dannenberg Notifies Pacira Biosciences, Inc. (“Pacira” or the “Company”) (NASDAQ: PCRX) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
February 21, 2025
From
Lowey Dannenberg, P.C.
Via
GlobeNewswire
Pacira to Report 2024 Financial Results on Thursday February 27, 2025
February 20, 2025
From
Pacira BioSciences
Via
GlobeNewswire
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira
February 19, 2025
From
Faruqi & Faruqi LLP
Via
GlobeNewswire
Lowey Dannenberg Notifies Pacira Biosciences, Inc. (“Pacira” or the “Company”) (NASDAQ: PCRX) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
February 18, 2025
From
Lowey Dannenberg, P.C.
Via
GlobeNewswire
Lowey Dannenberg Notifies Pacira Biosciences, Inc. (“Pacira” or the “Company”) (NASDAQ: PCRX) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $100,000 in Losses to Contact the Firm
February 14, 2025
From
Lowey Dannenberg, P.C.
Via
GlobeNewswire
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PCRX
February 14, 2025
From
The Rosen Law Firm PA
Via
GlobeNewswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages Pacira BioSciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PCRX
February 08, 2025
From
The Rosen Law Firm PA
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.